Related Experiment Videos
Transplantation resistance to a Rous sarcoma virus-induced tumor in mice immunized with v-src protein
N Kuzumaki1, H Fujita, H Dosaka
1Laboratory of Molecular Genetics, Hokkaido University School of Medicine, Sapporo, Japan.
Abstract:
It is of great interest in tumor immunology to know whether oncogene products could be used not only as tumor markers for cancer diagnosis, but also as immunogens for cancer therapy. BALB/c mice immunized with syngeneic fibroblasts, Escherichia coli cells producing p60v-src, or the purified p60v-src protein extracted from the E. coli producer cells showed transplantation resistance to a Rous sarcoma virus-induced tumor but not a Kirsten sarcoma virus-induced tumor. In contrast, mice immunized with cells not producing p60v-src or their derived proteins or with chicken ovalbumin did not show any significant resistance. These findings suggest that p60v-src can act as a specific transplantation rejection antigen in mice.
Insights
Oncogene products like p60v-src show potential as cancer immunogens. Mice immunized with p60v-src developed resistance to specific tumors, suggesting its role as a transplantation rejection antigen.
Area of Science:
- Tumor immunology
- Oncogene research
- Cancer therapy
Background:
- Investigating oncogene products for cancer diagnosis and therapy is crucial.
- Understanding the immunogenicity of oncogene products is key to developing novel cancer treatments.
Purpose of the Study:
- To determine if oncogene products, specifically p60v-src, can serve as immunogens for cancer therapy.
- To assess the potential of p60v-src as a specific transplantation rejection antigen.
Main Methods:
- BALB/c mice were immunized with syngeneic fibroblasts, Escherichia coli producing p60v-src, or purified p60v-src protein.
- Immunized mice were challenged with Rous sarcoma virus-induced and Kirsten sarcoma virus-induced tumors.
- Control groups received non-p60v-src producing cells or chicken ovalbumin.
Main Results:
- Mice immunized with p60v-src demonstrated transplantation resistance to Rous sarcoma virus-induced tumors.
- No significant resistance was observed against Kirsten sarcoma virus-induced tumors.
- Control groups showed no significant tumor resistance.
Conclusions:
- p60v-src functions as a specific transplantation rejection antigen in mice.
- These findings support the potential of oncogene products as therapeutic cancer immunogens.